Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Talimogene laherparepvec - Amgen

Drug Profile

Talimogene laherparepvec - Amgen

Alternative Names: AMG-678; IMLYGIC; JS1/34.5- /47-/GM-CSF; OncoVEX; OncoVEXGM-CSF; T-VEC

Latest Information Update: 30 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioVex
  • Developer Amgen; BioVex; H. Lee Moffitt Cancer Center and Research Institute; M. D. Anderson Cancer Center; Merck & Co; Roche; UNC Lineberger Comprehensive Cancer Center; University of Iowa
  • Class Gene therapies; Granulocyte-macrophage colony-stimulating factors; Oncolytic viruses
  • Mechanism of Action Apoptosis stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Malignant melanoma
  • Phase II Breast cancer; Soft tissue sarcoma
  • Phase I/II Malignant pleural effusion
  • Phase I Colorectal cancer; Solid tumours
  • No development reported Head and neck cancer; Liver cancer; Pancreatic cancer

Most Recent Events

  • 26 Aug 2019 Amgen in collaboration with Merck plans the phase II MASTERKEY-115 trial for Malignant melanoma(Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in January 2020 (Intralesional) (NCT04068181)
  • 31 May 2019 Efficacy data from a phase II trial in Melanoma presented at the 55th Annual Meeting of the American Society of Clinical Oncology (ASCO-2019)
  • 28 May 2019 No recent reports of development identified for phase-I development in Head-and-neck-cancer(Combination therapy, Metastatic disease, Second-line therapy or greater) in Australia (Intralesional, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top